N-ethyl-N-methyloxetan-3-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧杂环丁烷
• 英文名称: N-ethyl-N-methyloxetan-3-amine
• 化学式: C₆H₁₃NO
• 分子量: 115.17
• InChiKey: CUXLTNNOWSLRAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• BENZODICYCLOALKANE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20190161468A1

  公开（公告）日：2019-05-30

  It is provided herein a benzobicycloalkane derivative, and a preparation method and use thereof. In particular, it is provided herein a compound of Formula (I), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, a preparation method, and a use thereof in preparation of drugs for treating pain.

  本文提供了一种苯并螺环烷衍生物，以及其制备方法和用途。具体而言，本文提供了一种式（I）化合物，或其药用可接受的盐、立体异构体或溶剂化合物，以及其制备方法，并用于制备治疗疼痛药物的用途。
• [EN] THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES, LEURS COMPOSITIONS ET MÉTHODES D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017140825A1

  公开（公告）日：2017-08-24

  Compounds of Formula (I) salts thereof and and methods of use as Janus kinase inhibitors are described herein.

  本文描述了化合物(I)的盐及其用作Janus激酶抑制剂的方法。
• [EN] PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS<br/>[FR] DÉRIVÉS D'AMINO PYRIDAZINYLE UTILISÉS EN TANT QU'INHIBITEURS D'ALK5
  申请人：CHIESI FARM SPA

  公开号：WO2022013307A1

  公开（公告）日：2022-01-20

  The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.

  本发明涉及一种通式（I）的化合物，抑制转化生长因子-β（TGF-β）类型I受体（ALK5），制备这种化合物的方法，包含它们的药物组合物以及它们的治疗用途。本发明的化合物可能对哺乳动物中ALK5信号通路失调相关的疾病或病症的治疗有用。
• Spiropyrrolidine derived antiviral agents
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US11339170B1

  公开（公告）日：2022-05-24

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

  本发明揭示了式（I）的化合物及其药学上可接受的盐：可抑制冠状病毒复制活性。本发明还涉及包含式（I）的化合物或其药学上可接受的盐的制药组合物，以及治疗或预防受冠状病毒感染的患者的方法，包括向患者施用式（I）的化合物或其药学上可接受的盐的治疗有效量。
• QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS
  申请人：Principia Biopharma, Inc.

  公开号：US20160130268A1

  公开（公告）日：2016-05-12

  Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公开了一种纤维母细胞生长因子抑制剂（FGFR）化合物，因此对于通过抑制FGFR可治疗的疾病具有用处。还公开了含有这种化合物的药物组合物和制备这种化合物的过程。